Lantheus Holdings (LNTH) Cost of Revenue (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Cost of Revenue of $146.4 million for Q1 2026, up 8.4% year-over-year from $135.1 million in Q1 2025, and down 11.75% quarter-over-quarter from $165.9 million in Q4 2025.
Lantheus Holdings (LNTH) Cost of Revenue (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Cost of Revenue for 13 consecutive years, with $146.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 8.4% year-over-year to $146.4 million; the TTM figure through Mar 2026 stood at $611.0 million (up 10.58% YoY), while the FY2025 annual figure was $599.7 million, up 9.9% from the prior year.
- Cost of Revenue fell to $146.4 million in Q1 2026 per LNTH's latest filing, from $165.9 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $223.7 million in Q1 2023 and bottomed at $79.8 million in Q1 2022.
- Historically, Cost of Revenue has averaged $131.3 million across 5 years, with a median of $135.1 million in 2025.
- Annual changes were most pronounced in 2023 — Cost of Revenue surged 180.3% — and 2024, when it slumped 42.72%.
- Lantheus Holdings' Cost of Revenue stood at $96.0 million in 2022, then grew by 29.31% to $124.1 million in 2023, then advanced by 14.85% to $142.6 million in 2024, then climbed by 16.38% to $165.9 million in 2025, then retreated by 11.75% to $146.4 million in 2026.
- Business Quant data shows LNTH's Cost of Revenue at $146.4 million in Q1 2026, $165.9 million in Q4 2025, and $161.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | 146.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146.33 Mn |
| Jun 30, 2026 | 146.33 Mn |
| Mar 31, 2026 | 146.41 Mn |
| Mar 31, 2026 | 146.41 Mn |
| Dec 31, 2025 | 165.91 Mn |
| Dec 31, 2025 | 165.91 Mn |
| Sep 30, 2025 | 161.65 Mn |
| Sep 30, 2025 | 161.65 Mn |
| Jun 30, 2025 | 137.03 Mn |
| Jun 30, 2025 | 137.03 Mn |
| Mar 31, 2025 | 135.06 Mn |
| Mar 31, 2025 | 135.06 Mn |
| Dec 31, 2024 | 142.57 Mn |
| Dec 31, 2024 | 142.57 Mn |
| Sep 30, 2024 | 136.61 Mn |
| Sep 30, 2024 | 136.61 Mn |
| Jun 30, 2024 | 138.32 Mn |
| Jun 30, 2024 | 138.32 Mn |
| Mar 31, 2024 | 128.13 Mn |
| Mar 31, 2024 | 128.13 Mn |